Nuvalent is a biotechnology company focused on developing precisely targeted therapies for people with cancer. Drawing on expertise in chemistry and structure-based drug discovery, the company designs small-molecule medicines intended to inhibit clinically proven kinase targets while addressing challenges such as treatment resistance and selectivity. Its research and development approach is informed by collaboration with physician-scientists, helping identify patient needs and limitations in existing treatments.

Nuvalent’s work spans discovery, clinical development, and the advancement of targeted cancer medicines. The company has announced a newly approved therapy for locally advanced ROS1-positive non-small cell lung cancer and also maintains a broader development pipeline. Its teams cover chemistry, biology, clinical operations, pharmaceutical development, regulatory affairs, medical affairs, and other functions that support the development and delivery of therapies.

Nuvalent states that its purpose is to use scientific expertise to address the needs of patients with cancer. As of July 15, 2026, GSK had completed its acquisition of Nuvalent, bringing the company into GSK’s organization.